Premium
P1–246: International, multicenter training and validation of CSF Alzheimer's biomarker assays
Author(s) -
Oberoi Pankaj,
Umek Robert,
Puskar Nyssa,
Lewis Jennifer,
Dunty Jill,
Stewart David,
Wohlstadter Jacob
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.470
Subject(s) - protocol (science) , consistency (knowledge bases) , biomarker , multicenter study , external quality assessment , sample (material) , medicine , statistics , computer science , mathematics , pathology , chromatography , biology , artificial intelligence , chemistry , biochemistry , alternative medicine , randomized controlled trial
pathogenesis. Despite accumulating evidence for the importance of Ab oligomers, currently there is no established method for allowing routine monitoring of Ab oligomers. We developed a platform technology called Multimer Detection System (MDS), which can detect oligomeric proteins in blood. In this study, we focused on examination of influence of anticoagulant type and sample preparationmethod for Ab oligomer detection in samples of patients with AD using MDS. Methods: Blood samples were collected in EDTA or heparin containing tubes and centrifuged at 850g for 30 min. In MDS, epitope-overlapping N-terminal Ab antibodies were used for capturing and detecting of Ab. Using this system, we tested Ab oligomers in samples from 20 patients with clinically characterized AD and 20 healthy normal.Results: For detection of Ab oligomers, different results came out depend on types of anticoagulant and changes in method of sample preparation. Conclusions:We confirmed influence of anticoagulant type and sample preparation method for Ab oligomers detection in AD sample. Especially, the difference in levels of Ab oligomers between AD and healthy normal was significantly increased by optimizing the sample preparation method.